Please select the option that best describes you:
Would you use Ibrutinib plus Venetoclax as second line therapy in relapsed/refractory mantle cell lymphoma?
The recent NEJM phase II trial http://www.nejm.org/doi/full/10.1056/NEJMoa1715519?query=featured_home looked at a small cohort of 24 patients and showed a significantly higher response rate compared to historical results of ibrutinib monotherapy.
Answer from: Medical Oncologist at Academic Institution
I may consider this for the right patient with Mantle cell lymphoma that has relapsed with TP53 and high risk prognostic score. Even though the data is very exciting it is a single arm study with a small patient cohort, I would want to see a randomized data to make a definitive switch. The CR rates ...
Sign in or Register to read more
Answer from: Medical Oncologist at Community Practice
Thank you for your quick answer. The data, although a small non-randomized sample, does look exciting. Such high and durable responses in a disease where there aren't many good refractory treatments. It is also interesting to note that only 17% of the patients had Bendamustine in their p...